Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cannon

Showing results (411-420 of 1,137) with videos related to

Pageof 114
Sort By:
Seminars in Immunology|November 4, 2004
Mechanisms of antigen receptor evolutionDonna D Eason, John P Cannon, Robert N Haire, et al.
The American Journal of Cardiology|August 23, 2006
Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteersMatthew J Price, Jacqueline L Coleman, Steven R Steinhubl, et al.
Diabetes, Obesity & Metabolism|September 8, 2015
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesR Chilton, I Tikkanen, C P Cannon, et al.
Circulation|November 8, 2017
Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination SurveyBarry Burstein, Kathleen K Altobelli, Ken Williams, et al.
Reviews in Cardiovascular Medicine|October 31, 2003
Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunctionGregg C Fonarow, William T Abraham, Christopher P Cannon, et al.
Journal of Clinical Lipidology|May 12, 2019
PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumabEric Bruckert, Dean J Kereiakes, Michael J Koren, et al.
Journal of the American College of Cardiology|November 6, 2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trialChristopher P Cannon, Steen Husted, Robert A Harrington, et al.
Seminars in Immunology|December 17, 2009
Recognition of additional roles for immunoglobulin domains in immune functionJohn P Cannon, Larry J Dishaw, Robert N Haire, et al.
Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology|January 1, 1995
Cyanide antagonism with carrier erythrocytes and organic thiosulfonatesI Petrikovics, E P Cannon, W D McGuinn, et al.
American Heart Journal|December 22, 2005
Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarctionMarc S Sabatine, David A Morrow, Carolyn H McCabe, et al.
Pageof 114

Showing results (411-420 of 1,137) with videos related to

Sort By:
Pageof 114
Seminars in Immunology|November 4, 2004
Mechanisms of antigen receptor evolutionDonna D Eason, John P Cannon, Robert N Haire, et al.
The American Journal of Cardiology|August 23, 2006
Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteersMatthew J Price, Jacqueline L Coleman, Steven R Steinhubl, et al.
Diabetes, Obesity & Metabolism|September 8, 2015
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesR Chilton, I Tikkanen, C P Cannon, et al.
Circulation|November 8, 2017
Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination SurveyBarry Burstein, Kathleen K Altobelli, Ken Williams, et al.
Reviews in Cardiovascular Medicine|October 31, 2003
Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunctionGregg C Fonarow, William T Abraham, Christopher P Cannon, et al.
Journal of Clinical Lipidology|May 12, 2019
PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumabEric Bruckert, Dean J Kereiakes, Michael J Koren, et al.
Journal of the American College of Cardiology|November 6, 2007
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trialChristopher P Cannon, Steen Husted, Robert A Harrington, et al.
Seminars in Immunology|December 17, 2009
Recognition of additional roles for immunoglobulin domains in immune functionJohn P Cannon, Larry J Dishaw, Robert N Haire, et al.
Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology|January 1, 1995
Cyanide antagonism with carrier erythrocytes and organic thiosulfonatesI Petrikovics, E P Cannon, W D McGuinn, et al.
American Heart Journal|December 22, 2005
Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarctionMarc S Sabatine, David A Morrow, Carolyn H McCabe, et al.
Pageof 114